This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Fri Jun 12, 4:44AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cullinan Management (CGEM) and Veeva Systems (VEEV) with bullish sentiments.

Introducing TipRanks MCP for Agents

Cullinan Management (CGEM)

In a report released yesterday, Marc Frahm from TD Cowen maintained a Buy rating on Cullinan Management. The company’s shares closed last Wednesday at $12.05.

According to TipRanks.com, Frahm is a 5-star analyst with an average return of 18.2% and a 49.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Acrivon Therapeutics, Inc., and Monte Rosa Therapeutics. ;'>

Cullinan Management has an analyst consensus of Strong Buy, with a price target consensus of $33.56, implying a 155.4% upside from current levels. In a report issued on June 7, BTIG also maintained a Buy rating on the stock with a $38.00 price target.

See the top stocks recommended by analysts >>

Veeva Systems (VEEV)

In a report released yesterday, Stan Berenshteyn from Wells Fargo maintained a Buy rating on Veeva Systems, with a price target of $320.00. The company’s shares closed last Wednesday at $163.76.

According to TipRanks.com, Berenshteyn is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 43.6% success rate. Berenshteyn covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Omada Health, Inc., and Health Catalyst. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $236.68 average price target, which is a 41.7% upside from current levels. In a report issued on May 26, TipRanks – Google also upgraded the stock to Buy with a $179.00 price target.

Read More on CGEM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).